Physician profile
John K Ma
NPI 1205067758
$901.92
in general payments reported to CMS, 2019-2025
12 companies · $361 in 2025
The $361 reported for 2025 was more than what a typical Radiation Oncology provider received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $149 · 2020: $14.50 · 2022: $106 · 2023: $30.66 · 2024: $240 · 2025: $361.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $632.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $631.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $508.69 | 2023-2025 | Intellis Adaptivestim, Inceptiv |
| Ge Healthcare | $106.36 | 2022 | |
| Stryker Corporation | $105.99 | 2025 | Mild Device Kit |
| Novartis Pharmaceuticals Corporation | $31.81 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.04 | 2019 | |
| Janssen Biotech, INC. | $28.04 | 2019-2020 | |
| Genzyme Corporation | $21.70 | 2019 | |
| Incyte Corporation | $17.05 | 2019 | |
| Boston Scientific Corporation | $16.97 | 2025 | Intracept |
| Takeda Pharmaceuticals U.S.A., INC. | $11.66 | 2019 | |
| Clovis Oncology, INC. | $11.37 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $11.24 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Ma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.